Literature DB >> 2926160

Association of recurrent chlamydial infection with gonorrhea.

B E Batteiger1, J Fraiz, W J Newhall, B P Katz, R B Jones.   

Abstract

To determine whether concurrent gonorrhea reactivates latent chlamydial infection, we studied 74 recurrent chlamydial infections and the effect of concurrent gonorrhea at the recurrent episode on the chlamydial serovar identified. Serotyping of 74 recurrent pairs of chlamydial isolates from patients attending a sexually transmitted diseases clinic indicated that 47.1% (16 of 34) with gonorrhea at the time of recurrence harbored chlamydiae of the same serovar as at the initial infection, while only 22.5% (9 of 40) without gonorrhea had the same serovar (P = .03). The proportion of recurrences by the same serovar in the group without gonorrhea did not differ from the proportion predicted by a random exposure model (22.2% vs. 18.4%, P = .46), while the proportion in the gonorrhea group did (47.1% vs. 19.8%, P less than .0001). The possibility of reinfection did not appear more likely in the group with gonorrhea than in the group without. These observations support the hypothesis that concurrent gonorrhea can reactivate latent chlamydial infection.

Entities:  

Mesh:

Year:  1989        PMID: 2926160     DOI: 10.1093/infdis/159.4.661

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Population-based genetic and evolutionary analysis of Chlamydia trachomatis urogenital strain variation in the United States.

Authors:  Kim Millman; Carolyn M Black; Robert E Johnson; Walter E Stamm; Robert B Jones; Edward W Hook; David H Martin; Gail Bolan; Simon Tavaré; Deborah Dean
Journal:  J Bacteriol       Date:  2004-04       Impact factor: 3.490

2.  Comparison of immunotyping of Chlamydia trachomatis by indirect fluorescent-antibody staining and radioimmunoassay.

Authors:  B J van der Pol; R B Jones
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

Review 3.  Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies.

Authors:  Byron E Batteiger; Fujie Xu; Robert E Johnson; Michael L Rekart
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

4.  Study of the prevalence and association of ocular chlamydial conjunctivitis in women with genital infection by Chlamydia trachomatis, Mycoplasma genitalium and Candida albicans attending outpatient clinic.

Authors:  Rania Abdelmonem Khattab; Maha Mohssen Abdelfattah
Journal:  Int J Ophthalmol       Date:  2016-08-18       Impact factor: 1.779

5.  Multicenter evaluation of AMPLICOR and automated COBAS AMPLICOR CT/NG tests for Neisseria gonorrhoeae.

Authors:  D H Martin; C Cammarata; B Van Der Pol; R B Jones; T C Quinn; C A Gaydos; K Crotchfelt; J Schachter; J Moncada; D Jungkind; B Turner; C Peyton
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

6.  External quality assessment for detection of Chlamydia trachomatis.

Authors:  V J Chalker; H Vaughan; P Patel; A Rossouw; H Seyedzadeh; K Gerrard; V L A James
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

7.  Repeated Chlamydia trachomatis genital infections in adolescent women.

Authors:  Byron E Batteiger; Wanzhu Tu; Susan Ofner; Barbara Van Der Pol; Diane R Stothard; Donald P Orr; Barry P Katz; J Dennis Fortenberry
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

Review 8.  Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis.

Authors:  W L Beatty; R P Morrison; G I Byrne
Journal:  Microbiol Rev       Date:  1994-12

9.  The major outer membrane protein of a single Chlamydia trachomatis serovar can possess more than one serovar-specific epitope.

Authors:  B E Batteiger
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

Review 10.  Human ecology and behavior and sexually transmitted bacterial infections.

Authors:  K K Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.